Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Long-Term Storage Stability of Analyte – V 2.0

Posted on By

BA-BE Studies: SOP for Long-Term Storage Stability of Analyte – V 2.0

Standard Operating Procedure for Long-Term Storage Stability of Analyte in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/176/2025
Supersedes SOP/BA-BE/176/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the process for assessing the long-term stability of analytes in plasma samples stored at -20°C and/or -70°C over extended periods as part of bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to the bioanalytical laboratory performing method validation and sample analysis for BA/BE studies, specifically evaluating analyte stability in plasma samples stored for long durations.

3.

Responsibilities
  • Analyst: Prepares and stores QC samples and performs analysis after designated storage periods.
  • Reviewer: Evaluates stability data and ensures compliance with acceptance criteria.
  • QA Officer: Verifies documentation and ensures SOP and regulatory guideline adherence.

4. Accountability

The Bioanalytical Lab Manager is accountable for ensuring long-term storage stability is evaluated, documented, and incorporated in validation reports or regulatory submissions as required.

5. Procedure

5.1 Sample Preparation and Storage

  1. Prepare at least six replicates of LQC and HQC samples from the same plasma lot used during validation.
  2. Label vials with the following:
    • Study code
    • Analyte
    • QC level
    • Date of preparation
    • Designated stability time point
  3. Store samples in deep freezers at -20°C or -70°C as defined in the method validation protocol.
  4. Record entries in Annexure-1: Long-Term Storage Sample Log.

5.2 Time Points and Duration

  1. Commonly assessed durations include 30, 60, 90, 180, and 365 days.
  2. Retrieve and analyze stability samples at specified intervals.
  3. Do not allow samples to undergo freeze-thaw cycles before analysis.

5.3 Sample Analysis

  1. Analyze stability samples alongside fresh calibration standards and system suitability samples.
  2. Use validated LC-MS/MS methods to quantify analyte concentration.
  3. Document and process raw data in accordance with method SOP.

5.4 Acceptance Criteria

  1. Mean measured concentrations for LQC and HQC must be within ±15% of nominal values.
  2. %CV should be ≤15% for replicate values at each QC level.
  3. Document results in Annexure-2: Long-Term Stability Summary.

5.5 Reporting and Documentation

  1. Prepare a report containing:
    • Raw data printouts
    • System suitability results
    • QC charts
    • Acceptance conclusions
  2. Submit to QA for review and approval before finalizing the validation/study report.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LQC: Low Quality Control
  • HQC: High Quality Control
  • %CV: Percent Coefficient of Variation
  • QA: Quality Assurance

7. Documents

  1. Long-Term Storage Sample Log – Annexure-1
  2. Long-Term Stability Summary – Annexure-2

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
  • Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Long-Term Storage Sample Log

Sample ID QC Level Storage Temp Prep Date Target Analysis Date Stored By
BE176-LTS-01 LQC -70°C 17/04/2025 17/10/2025 Rajesh Kumar

Annexure-2: Long-Term Stability Summary

QC Level Nominal (ng/mL) Mean Measured %CV % Difference Status
HQC 1500.0 1486.0 3.8 -0.9% Accepted
LQC 20.0 19.4 4.5 -3.0% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial version New SOP QA Head
17/04/2025 2.0 Clarified time points, annexures, and regulatory references Annual Review QA Head
See also  BA-BE Studies: SOP for Ensuring Sample Integrity Before Analysis - V 2.0
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Document Control and Distribution – V 2.0
Next Post: Sterile Injectable Manufacturing: SOP for Aseptic Manufacturing of Prefilled Syringes – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version